Amoxicillin for Oral Suspension- Newlystar (Ningbo) Medtech Co., Ltd.

Newlystar (Ningbo) Medtech Co., Ltd.

We only export finished medicines. We are a professional trading company, if you must make deal with manufacturer, please find manufacturer directly.
We export to Europe, to Latin American, to Asia, to Africa. We have clients in more than 30 countries.
Each year, we have big deal with a lot manufacturers in China, because the quantity is big, our price is competitive.
And to make our business longer and stable, we only deal with manufacturers with good quality.

We have a quality department dealing with registration dossier and help manufacturers pass higher GMP inspection. We are the best one in China in this issue.

Above are features of Newlystar.
If you want read more information about our company, please go ahead. But usually, offical company introduction, doesn't have many useful information.(That is my personal opinion.)

Newlystar Medtech cooperate with state of the art facilities in China and export medicines to 30+ countries worldwide. Include East Europe, Central and southeast Asia, Latin America, Africa etc. We also contract manufacture for European companies.

Newlystar-Medtech is a well established and professional supplier of Finished Pharmaceutical, Active Pharmaceutical Ingredient(API) and Medical Devices. With a proven track record of passed years, Newlystar-Medtech has been recognized by her customers as a high-quality and reliable supplier not only on products, but also on assistance for audit and improvement of GMP level, quality management system, EHS management system and registration dossier support, etc.
The essence of Newlystar-Medtech's activites, is a commitment to her customers with professional service and high-quality products with effective cost and innovative solutions. All pharmacists work in Newlystar-Medtech like a bridge link the customers and Chinese manufacturers, especially, their professional working is to make the formulation manufacturers who is familiar with Chinese Pharmacopoeia to understand well the international requirement, to ensure the success of customers.
The advantages on professional working and strongly representative base on first-class manufacturing partners in China, enable Newlystar-Medtech to provide her customers with a wide range and high-tech products, best services and capabilities for their actions in tender, distributing and improvement in their national healthcare system. Newlystar-Medtech also dedicates herself to sourcing quality medical products for Chinese market.

Services and capabilities include:
1. Sourcing quality manufacturer
2. Contract manufacturing;
3. Conduct audits to suppliers (pharmaceutical plants);
4. Consultation on audit and improvement of GMP level, quality management system and EHS management system;
5. Regulatory support, registration dossier working;

Newlystar Medtech, your professional one-stop China Souring Partner.

Home>Product>Amoxicillin for Oral Suspension

Amoxicillin for Oral Suspension

FOB Price:Get Latest Price >
Min.Order:20000 Box(es)
Payment Terms:L/C , T/T

Favorite

Newlystar (Ningbo) Medtech Co., Ltd.

Business Type:Trader

Country/Region:China

Ddu Verified

HOT Rank

8/10

Product Information

Dosage Form:Granule
Route of Administration:Oral
Shelf Life:3 years
Storage:Sealed

Description

Product : Amoxicillin for oral Suspension

Specification : 250mg/5ml; 400mg/5ml

Standard : BP, USP

Packing : one bottle/box

Description:

Each 5 mL of reconstituted suspension for oral administration contains 250 mg or 400 mg amoxicillin as the trihydrate.

Indications and usage:

Amoxicillin for oral suspension is indicated in the treatment of infections due to susceptible (ONLY β-lactamase-negative) strains of the designated microorganisms in the conditions listed below:

Infections of the ear, nose, and throat – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Infections of the genitourinary tract– due to E. coli, P. mirabilis, or E. faecalis.

Infections of the skin and skin structure– due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli.

Infections of the lower respiratory tract– due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae.

Gonorrhea, acute uncomplicated (ano-genital and urethral infections)– due to N. gonorrhoeae (males and females).

H. pylori eradication to reduce the risk of duodenal ulcer recurrence

Triple Therapy

Amoxicillin/Clarithromycin/Lansoprazole

Amoxicillin for oral suspension, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.)

Dual Therapy

Amoxicillin/Lansoprazole

Amoxicillin for oral suspension, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1 year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.)

To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin for oral suspension and other antibacterial drugs, amoxicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Indicated surgical procedures should be performed.